Sio Gene Therapies Inc. — Operating Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/8716cdcd-79ee-432b-b34f-e1dd29d839ca/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2021 | $-71.6M | 2021-04-01 – 2022-03-31 | evidence 0001636050-22-000035 |
| FY 2020 | $-32.6M | 2020-04-01 – 2021-03-31 | evidence 0001636050-21-000059 |
| FY 2019 | $-72.2M | 2019-04-01 – 2020-03-31 | evidence 0001636050-20-000028 |
| FY 2018 | $-128.9M | 2018-04-01 – 2019-03-31 | evidence 0001636050-19-000053 |
| FY 2017 | $-220.7M | 2017-04-01 – 2018-03-31 | evidence 0001636050-18-000014 |
| FY 2016 | $-182.0M | 2016-04-01 – 2017-03-31 | evidence 0001636050-17-000029 |
| FY 2015 | $-133.2M | 2015-04-01 – 2016-03-31 | evidence 0001636050-16-000042 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).